A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib (IVO) monotherapy and azacitidine (AZA) monotherapy in adult patients with hypomethylating agent (HMA) naive myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation (PyramIDH study)

A new clinical trial is testing whether a daily pill can replace standard injections for a specific group of patients with a bone marrow disorder. The trial focuses on people with myelodysplastic syndromes (MDS) whose cancer cells carry a mutation in the IDH1 gene. These patients have not yet received any treatment. The standard drug, azacitidine, must be given as an injection or infusion in cycles lasting 28 days. The experimental drug, ivosidenib, is taken orally every day. The study directly compares how well each drug shrinks or eliminates abnormal cells in the bone marrow. If ivosidenib works as well as the injected drug, patients could avoid frequent hospital visits for infusions. That would simplify treatment and reduce the burden on both patients and the healthcare system. The trial also tracks side effects and quality of life, so the results will show not just whether the pill works, but whether it is easier to live with. This is a late-stage trial designed to generate evidence that could change standard care for this specific genetic subtype of MDS. If successful, it would offer a more convenient treatment option for a group of patients who currently have limited choices.